XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer https://lnkd.in/gqqYKiEB
XBiotech USA, Inc.
Biotechnology Research
Austin, Texas 6,857 followers
Next Generation Antibody Therapy
About us
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. Unlike previous generations of antibody therapies, XBiotech’s True Human™ antibodies are 100 percent human, derived from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human™ antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability. XBiotech is currently advancing a robust pipeline of antibody therapies to exceed the standards of care in oncology, inflammatory conditions and infectious diseases. The Company's broad pipeline of True Human™ antibodies are able to potentially deliver unmatched safety and efficacy because they are cloned directly from individual donors who possess natural immunity against certain targeted diseases. As such, True Human™ antibodies retain their natural physiology and tolerance profile, having passed the rigors of immune selection in the body.
- Website
-
http://www.xbiotech.com
External link for XBiotech USA, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Austin, Texas
- Type
- Public Company
- Founded
- 2005
- Specialties
- first-in-class monoclonal antibody
Locations
-
Primary
Get directions
5217 Winnebago Ln
Austin, Texas 78744, US
Employees at XBiotech USA, Inc.
Updates
-
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus https://lnkd.in/gbq-MaSK
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus | XBiotech
investors.xbiotech.com
-
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis https://lnkd.in/gU5cwHyq
-
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke https://lnkd.in/ggheB2Pm
-
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial https://lnkd.in/d6dYBNWj
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial | XBiotech
investors.xbiotech.com